Novavax, Inc. (NVAX)
Pre-market:
| Previous close | 3.9700 |
| Open | 3.9900 |
| Bid | 4.0300 x 1000 |
| Ask | 4.1300 x 600 |
| Day's range | 3.9100 - 4.1300 |
| 52-week range | 3.5300 - 11.3600 |
| Volume | |
| Avg. volume | 7,326,375 |
| Market cap | 569.609M |
| Beta (5Y monthly) | 1.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.4100 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.40 |
ZacksHow to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Insider Monkey12 Most Shorted Stocks in 2024
In this article, we will take a detailed look at the 12 Most Shorted Stocks in 2024. For a quick overview of such stocks, read our article 5 Most Shorted Stocks in 2024. Short-sellers may be annoying for corporations (and Redditors?), but investors usually find themselves thanking these companies for doing the often back-breaking and excruciating research that […]
GlobeNewswireShah Capital nominates two highly qualified independent director candidates for Novavax
Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price Shah Capital which owns 6.7% of Novavax, in a letter to the board says that the low share price reflects the board and management’s failure to capitalize on Novavax’s many significant competitive advantages and TAM opportunities The letter highlights that the underperformance is self-inflicted and is the result of reactive leadership and outd
